In recent FDA Phase 2 trials, a single dose of the experimental psychedelic luvesilocin eliminated postpartum depression symptoms in 71% of patients within seven days. The breakthrough medication will enter Phase 3 trials by late 2026.

In the Phase 2 study, 77% of postpartum women who received a psychedelic dose, 30mg of luvesilocin, had significant improvement in their postpartum depression. Overall, 71% had no symptoms of postpartum depression seven days after the psychedelic session.